<DOC>
	<DOCNO>NCT01513187</DOCNO>
	<brief_summary>Phase I / II , open , prospective , multicenter single-arm , Clinical Trial two stage : first stage determine optimal dose combination pazopanib interferon alfa-A2 treatment patient advance renal carcinoma second stage determine efficacy combination measure term response rate .</brief_summary>
	<brief_title>Pazopanib Combination With Interferon Alfa 2-A , Patients With Advanced Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Signed informed consent 2 . Age ≥ 18 year . 3 . Patients diagnose histologically clear cell carcinoma kidney metastatic unresectable locally advanced , previously untreated . However , Phase I may include patient primary tumor renal cell benefit drug patient renal cell carcinoma treat . 4 . Performance status ( ECOG ) 01 . 5 . Patients must measurable disease RECIST criterion V 1.1 . Progression document two month prior study entry . 6 . Patients may receive prior treatment antiVEGF agent , mTOR inhibitor cytokine . However , Phase I may include patient received previous treatment . 7 . Paraffin tumor sample available collection serum subject biomarker analysis previously / treatment study medication . 8 . Adequate Hematologic , liver kidney function . 9 . Women childbearing potential must use effective method birth control ( abstinence , intrauterine device [ IUD ] publish data show expected minimum rate failure le 1 % per year , method publish data show expect minimum rate failure le 1 % per year ) inclusion study continue use six month completion . Women childbearing age get negative pregnancy test urine serum ( minimum sensitivity 25 IU / L equivalent unit beta fraction human chorionic gonadotropin [ βHCG ] ) seven day prior randomization . 10 . Able swallow oral compound . 11 . Willingness ability attend schedule visit , follow treatment schedule undergo clinical trial study procedure 1 . History prior malignancy diagnose treat past 5 year except basal cell skin cancer prostate cancer incidentally detect previously treat . However , patient history malignancy free disease past 5 year , patient history nonmelanoma skin carcinomacompletelyresected carcinoma situ treat successfully participate study . In Phase I , patient diagnose previous concomitant malignant disease include . 2 . Presence metastases central nervous system ( CNS ) leptomeningeal carcinomatosis , except patient previously treat CNS metastasis , asymptomatic need corticosteroid anticonvulsant drug 3 month prior administer first dose drug study . Only required CNS imaging study ( compute tomography [ CT ] magnetic resonance image [ MRI ] ) clinically indicate individual history CNS metastases . 3 . Clinically significant gastrointestinal disorder may increase risk gastrointestinal bleeding include , limited : Active peptic ulcer disease Known metastatic lesion probable intraluminal bleeding Inflammatory bowel disease ( ulcerative colitis , Crohn 's disease ) gastrointestinal disorder increase risk perforation History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 28 day start study treatment . 4 . Clinically significant gastrointestinal abnormality may affect absorption investigational product limit : Malabsorption syndrome Major resection stomach small intestine Grade 3 diarrhea 5 . Patients active infection disease serious medical condition . 6 . Prolongation correct QT wave ( QTc ) &gt; 480 m baseline ECG accord Bazett formula . 7 . Subjects history one follow cardiovascular disease last 6 month prior inclusion study : Angioplasty stent placement Myocardial infarction Unstable Angina Coronary bypass surgery Symptomatic peripheral vascular disease Congestive heart failure Class II , III IV New York Heart Association ( NYHA ) 8 . Poorly control hypertension [ define systolic blood pressure ( SBP ) ≥ 140 mmHg diastolic blood pressure stress ( DBP ) ≥ 90 mmHg ] patient antihypertensive therapy . Note : commencement adjustment antihypertensive medication possible patient study start . In baseline period measure blood pressure least twice minimum interval 24 hour . The mean value SBP / DBP blood pressure read &lt; 140/90 mmHg include subject study . 9 . Background , last six month prior inclusion stroke ( include transient ischemic attack ) , pulmonary embolism deep vein thrombosis ( DVT ) untreated . Note : may include subject recent DVT receive anticoagulant least 6 month . 10 . Surgery trauma last 28 day , minor surgery ( eg. , Removal central venous catheter ) last 7 day prior inclusion unhealed wound , fracture , ulcer . 11 . Evidence active bleeding bleed diathesis . 12 . Hemoptysis within 6 week prior inclusion . 13 . Pregnant breastfeeding . 14 . Any medical condition ( eg . Uncontrolled infection ) , psychiatric serious / unstable may interfere safety patient , obtain informed consent compliance study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Advanced renal cell carcinoma</keyword>
	<keyword>SOGUG</keyword>
	<keyword>Pazopanib</keyword>
	<keyword>Pazopanib combination interferon alpha 2A</keyword>
</DOC>